Lewis Kevin R, McCrone Susan, Deiriggi Pamela, Bendre Sachin
Clinical Associate Professor, West Virginia University, School of Medicine, Charleston, West Virginia.
Professor, West Virginia University, School of Nursing, Morgantown, West Virginia.
J Spec Pediatr Nurs. 2017 Jan;22(1). doi: 10.1111/jspn.12162. Epub 2016 Oct 14.
The purpose of this study was to determine the effect of continuous glucose monitoring (CGM) on glycemic control in children, adolescents, and young adults ages 7-21 years with poorly controlled diabetes HbA1c 9.0% or more (74 mmol/mol IFCC).
The primary outcome was improvement in HbA1c. The secondary outcome included self-reported hypoglycemia. This 12-week study used a prospective, one-group, pre- and posttest pre-experimental design with a convenience sample. The study used the Medtronic Guardian CGM with Enlite Sensor.
Thirty-three subjects enrolled in the study. The mean age of the participants was 15.57 years, range was 11-20 years, 47.6% were male, and 52.4% were female. Twenty-one (63.6%) completed the final study visit. There was a clinically and statistically significant reduction of 1.46 (SD = 1.6711) (p = .001) in HbA1c at 12 weeks. Fifteen of the 21 participants (71.4%) had an HbA1c reduction of greater than 0.5%. The CGM monitor was worn a mean of 4.262 days a week. None of the subjects reported significant hypoglycemia while wearing the monitor. CGM was effective in improving glycemic control in this population with poorly controlled diabetes.
本研究旨在确定连续血糖监测（CGM）对7至21岁糖尿病控制不佳（糖化血红蛋白[HbA1c]≥9.0%[IFCC为74 mmol/mol]）的儿童、青少年及青年成人血糖控制的影响。
主要结局为HbA1c的改善情况。次要结局包括自我报告的低血糖情况。这项为期12周的研究采用前瞻性单组前后测实验前设计，样本为便利样本。研究使用美敦力Guardian CGM及Enlite传感器。
33名受试者参与了本研究。参与者的平均年龄为15.57岁，年龄范围为11至20岁，47.6%为男性，52.4%为女性。21名（63.6%）受试者完成了最终研究访视。12周时，HbA1c临床及统计学显著降低1.46（标准差=1.6711）（p = 0.001）。21名参与者中有15名（71.4%）HbA1c降低超过0.5%。CGM监测仪平均每周佩戴4.262天。在佩戴监测仪期间，没有受试者报告有显著低血糖情况。CGM对改善该糖尿病控制不佳人群的血糖控制有效。
